Types of Cancer We Treat

Pancreatic Cancer

Our highly experienced and knowledgable team of dedicated doctors combine innovative therapies, precision treatment, and evidence-based medicine to provide world-class care to people with pancreatic cancer. Our specialists are at the forefront of groundbreaking research, studying promising new treatments and pioneering methods for detecting pancreatic cancer earlier, when it’s most treatable.

Our experts create an individualized treatment plan for you, drawing on our expertise in endoscopic and surgical treatments as well as medical therapies. Learn more about our comprehensive care for pancreatic cancer at Perlmutter Cancer Center’s Pancreatic Cancer Center.

Find a Doctor & Schedule
Diagnosis
Surgery
Chemotherapy & Targeted Drugs
Radiation Therapy

Related News

Dr. Christopher Wolfgang Joins NYU Langone Health
Read Story
Dr. Tamas A. Gonda Joins NYU Langone Health
Read Story
Nerves Keep Pancreatic Cancer Cells from Starving
Read Story
New Platform Tests Multiple Treatments Simultaneously
Read Story
Medical Oncologist Advances Pancreatic Cancer Treatments
Read Story
Innovative Pancreatic Cancer Clinical Trial Begins Enrolling
Read Story
Pancreatic Cancer Cells Use Recycling to Evade Immunotherapy
Read Story
To Stop a Deadly Cancer, Cut Off Its Food Supply
Read Story
Pancreatic Tumor Cells Release Key Immune Signal
Read Story
Study Reveals How Pancreatic Cells Avert Starvation
Read Story
Expert Discusses Early Detection of Pancreatic Cancer
Read Story
New Program Aims to Stop Pancreatic Cancer Before It Starts
Read Story

Clinical Trials and Research Studies

Phase 5

A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

Learn More

Phase 1

A Phase 1 First-in Human Multi-Center Open Label Dose-Escalation Study to Determine the Safety Tolerability Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination with ABBV-181 in Subjects with Locally Advanced or Metastatic Solid Tumors (AbbVie M19-345)

Learn More

Phase 5

A Phase I study of Anetumab Ravtansine in Combination with either Anti-PD-1 Antibody or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma

Learn More

Phase 5

A MULTI-CENTER OPEN LABEL PHASE 1/2 STUDY OF CYT-0851 AN ORAL RAD51 INHIBITOR IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES AND ADVANCED SOLID TUMORS

Learn More
View All Related Clinical Trials (14)